Lyophilization is considered to be one of the most promising approaches to stabilize mRNA-LNP formulations and enhance their stability at refrigerated or even room temperatures.
However, lyophilization is a slow, expensive, poorly controlled, and labor-intensive process. Consequently, these disadvantages hamper the fast and cost-efficient development of mRNA-LNP vaccines.
We have created a White Paper describing the advantages associated with RheaVita’s NextGen continuous and controlled lyophilization. This drying technology allows the R&D team and the MSAT team to save money and staffing. It opens a path for seamless scaling-out without the need to reformulate lyophilization protocols. All this may result in a faster time to the market for your mRNA drug or vaccine.
